Drug Trial Radar · NCT00671918
Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma
Last checked: Nov 20, 2026Latest source record: Jun 17, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
186
Actual
Start
Apr 2008
Primary completion
Jun 2009
Study completion Jul 2009
Sponsor
- Lead sponsor
- Navidea BiopharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- May 5, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Data from this pivotal clinical trial will be used to support a marketing application (i.e., NDA) for Navidea's Lymphoseek for use in intraoperative localization of lymph tissue (nodes) in the lymphatic pathway draining the primary site of a tumor.
Conditions
- Breast Cancer
- Melanoma
Interventions
LymphoseekDrug
Breast Cancer: Intradermal admin of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site OR periareolar administration of Lymphoseek: Inject 0.2-.04 mL in multiple divided doses at the margin of the areola OR subareolar administration of Lymphoseek: Inject 0.2-0.4 in multiple divided injections or a single injection in subareolar area as a subcutaneous injection OR peritumor administration of Lymphoseek: Inject 2.0-4.0 mL in multiple divided injections, intraparenchemally surrounding the tumor or biopsy cavity. For melanoma pts intradermal administration of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Concordance of Blue Dye and LymphoseekTime frame: Surgery after injections of Lymphoseek and blue dye
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
Barbara Michna, M.D
Alexander City, Alabama
Helen Krontiras, M.D.
Birmingham, Alabama
Anne Wallace, M.D.
La Jolla, California
Ken Deck, M.D.
Laguna Hills, California
Steve Martinez, M.D.
Sacramento, California
Mark Faries, M.D.
Santa Monica, California
Eli Avisar, M.D.
Miami, Florida
Charles Cox, M.D.
Tampa, Florida
Vernon Sondak, M.D.
Tampa, Florida
Julian Kim, M.D.
Cleveland, Ohio
Bruce Averbook, M.D
Cleveland, Ohio
Stephen Povoski, M.D.
Columbus, Ohio
Thomas Frazier, M.D.
Bryn Mawr, Pennsylvania
Ned Carp, M.D.
Philadelphia, Pennsylvania
Schlomo Schneebaum, M.D.
Tel Aviv, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.